about
Horse bone marrow mesenchymal stem cells express embryo stem cell markers and show the ability for tenogenic differentiation by in vitro exposure to BMP-12.Biomarkers and Microscopic Colitis: An Unmet Need in Clinical Practice.Characterization of maternal antigen that embryos require (MATER/NLRP5) gene and protein in pig somatic tissues and germ cells.Isolation and differentiation potential of an equine amnion-derived stromal cell line.Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated FashionMicroscopic Colitis: What Do We Know About Pathogenesis?Effect of proton pump inhibitors on magnesium balance: is there a link to cardiovascular risk?MMX® technology and its applications in gastrointestinal diseases.Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier functionDevelopment of 23 individual TaqMan® real-time PCR assays for identifying common foodborne pathogens using a single set of amplification conditions.Effects of pre-mating nutrition on mRNA levels of developmentally relevant genes in sheep oocytes and granulosa cells.In vitro modulatory effect of omega-3 polyunsaturated fatty acid (EPA and DHA) on phagocytosis and ROS production of goat neutrophils.Escherichia coli lipopolysaccharides and Staphylococcus aureus enterotoxin B differentially modulate inflammatory microRNAs in bovine monocytes.Distribution of acute phase proteins in the bovine forestomachs and abomasumIn vitro modulation of caprine monocyte immune functions by ω-3 polyunsaturated fatty acids
P50
Q33433291-97CBBE4F-D923-426D-9EA8-7F6900507C4BQ33653647-65F32D81-855B-4B2F-B958-05F280D503F8Q35007229-EF05A565-9154-484C-A0BC-B5875D473591Q35681327-9350E5A6-EBB0-4BEE-A474-A04E19FADCAFQ37612050-0CF41B5D-3997-4406-B80C-3FCE653DA7CFQ38623461-CD47BA70-51B7-4602-9A05-FA355F862ACCQ38810419-EC8EE226-DDFB-46A0-8666-10BF0ECE87A8Q40095211-A72C5DA0-37F6-426A-8AF5-95A99AD3AA91Q40578397-727FB548-6C51-410E-A4D5-018DA9C961FAQ41231031-0C19C5DA-F5E7-4601-B010-F6DA8D77F561Q41385230-59A61004-9E5F-40AD-B287-3543FF3323E6Q43638751-E00DDF6C-0039-46D0-885B-DE8DE0210F13Q46036402-B2F29203-B395-42DF-B24A-A7F0FC92B809Q54342090-BD0F06B1-4D91-4733-9AFB-D22E86E6B5CDQ58856603-EE3A6730-340D-47B6-A0E3-D0A8104B88F6Q58856604-97BD8B3D-8A17-494A-B46E-E1B071418B65
P50
description
medical researcher
@en
onderzoeker
@nl
name
Laura Francesca Pisani
@ast
Laura Francesca Pisani
@en
Laura Francesca Pisani
@es
Laura Francesca Pisani
@nl
type
label
Laura Francesca Pisani
@ast
Laura Francesca Pisani
@en
Laura Francesca Pisani
@es
Laura Francesca Pisani
@nl
prefLabel
Laura Francesca Pisani
@ast
Laura Francesca Pisani
@en
Laura Francesca Pisani
@es
Laura Francesca Pisani
@nl
P106
P1153
25228151900
P21
P31
P496
0000-0002-9490-3723